Studies On Expressions Of TGF β1 And CTGF Of Bone Marrow Of Patients In Chronic Mountain Sickness

Objective The chronic mountain sickness (CMS) is a kind of erythrocyte hyper proliferative disease, the generation of which is directly related with theenvironmental conditions in the high altitude, such as hypobaric hypoxia, and is regulated by various hematopoietic growth factors (HGF) and apoptotic factorsAt present, the study of hematopoietic growth factors and apoptotic factors of chronic mountain sickness was too more, but the study of the change of bone marrow fibrosis was too less. The aim of this study was to explore the patholo-gycal roles of apoptosis and angiogenesis in the progenesis and progress of CMS by evaluating the expressions of TGFβ1 and CTGF in bone marrow of patients with CMS.Method The samples of bone marrow used in this study were obtained from 20 patients with CMS (CMS group) and 15 healthy adults (control group).The expressions of TGFβ1 and CTGF in bone marrows were detected using the SP immunohistochemistry technique. The results were analyzed comparatively.Results The positive rates of TGFβ1 and CTGF in CMS group were 75% and 80%,while 33.33% and 26.67% in control group.There were significant differences in the positive rates of TGFβ1and CTGF between these two groups, In the CMS group, there were positive correlations in the positive rates of TGFβ1and CTGF each other(r=0.532).Conclusion The results of this study showed that there were over expressions of TGFβ1 and CTGF increased in bone marrow of CMS, It suggested that hypoxia can lead to the expression of TGFβ1 and CTGF significantly increase, hypoxia took part in the process of tissue and organ fibrosis by cytokines TGFβ1 and CTGF, which suggested the possibility occurrence of fibrosis of bone marrow in patients. To study the relations between hypoxia and regulation of TGFβ1-CTGF and the information access of the various branches may provide a theoretical basis for the mechanism of fibrosis and the pathological changes of bone marrow in CMS patients, as well as important target molecular for the t-reatment and prognosis of the fibrosis of ischemia and hypoxic organs, It can providenew ideas for anti-fibrotic strategy in clinical.